Centre National De La Recherche Scientifique

National Institute of Health and Medical Research

Ecole Superieure De Physique Et De Chimie Industrielles De La Ville De Paris

Université De Paris

Université De Lille

Centre Hospitalier Régional Universitaire De Lille

Inserm

Joëlle Vinh

Luc Buee

Roberto Mallone

Georgia Afonso

Sergio Gonzalez-duque

Yann Verdier

Marie-Eliane Azoury

David Blum

Despite the notion that human CD8T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by β cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased β-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known β-cell antigens and several insulin granule proteins. Urocortin 3 was identified as a novel β-cell antigen, which was processed into HLA-A2- and HLA-A3-restricted epitopes recognized by circulating naive CD8T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from urocortin-3 and uses thereof for the diagnosis and treatment of T1D.

Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes

Growing community of inventors

Paris, France

Joëlle Vinh